Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Trinity Biotech (TRIB) Debt to Equity (2016 - 2024)

Trinity Biotech's Debt to Equity history spans 9 years, with the latest figure at -$2.1 for Q4 2024.

  • On a quarterly basis, Debt to Equity fell 24.05% to -$2.1 in Q4 2024 year-over-year; TTM through Dec 2024 was -$2.1, a 24.05% decrease, with the full-year FY2024 number at -$2.1, down 24.05% from a year prior.
  • Debt to Equity hit -$2.1 in Q4 2024 for Trinity Biotech, down from -$1.7 in the prior quarter.
  • Over the last five years, Debt to Equity for TRIB hit a ceiling of $6.66 in Q3 2022 and a floor of -$20.36 in Q4 2022.
  • Historically, Debt to Equity has averaged -$3.36 across 5 years, with a median of -$0.9 in 2021.
  • Biggest five-year swings in Debt to Equity: plummeted 20849.98% in 2022 and later surged 91.67% in 2023.
  • Tracing TRIB's Debt to Equity over 5 years: stood at -$0.03 in 2020, then plummeted by 275.55% to -$0.1 in 2021, then tumbled by 20849.98% to -$20.36 in 2022, then surged by 91.67% to -$1.7 in 2023, then decreased by 24.05% to -$2.1 in 2024.
  • Business Quant data shows Debt to Equity for TRIB at -$2.1 in Q4 2024, -$1.7 in Q4 2023, and -$20.36 in Q4 2022.